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A simple, rapid, economical and reliable high performance liquid chromatographic method has been 
developed and successfully applied in simultaneous determination of ethinyl estradiol and drospirenone 
in coated tablets. The HPLC method was performed on a LiChroCART® 100RP column (125x4 mm 
i.d., 5 µm) with acetonitrile:water 50:50 (v/v) as mobile phase, pumped at a flow rate of 1.0 mL.min-1. 
The fluorescence detection for ethinyl estradiol was made at λex= 280 nm and λem= 310 nm and a UV 
detection for drospirenone was made at 200 nm. The elution time for ethinyl estradiol and drospirenone 
were 4.0 and 5.7 min, respectively. The method was validated in accordance to USP 34 guidelines. The 
proposed HPLC method presented advantages over reported methods and is suitable for quality control 
assays of ethinyl estradiol and drospirenone in coated tablets.
Uniterms: Coated tablets/quantitative analysis. High performance liquid chromatography/quantitative 
analysis. Ethinyl estradiol/quantitative determination. Drospirenone/quantitative determination. 
Fluorescence detection. UV detection.
Um método simples, rápido, econômico e confiável foi desenvolvido empregando a cromatografia líquida 
de alta eficiência para a determinação simultânea de etinilestradiol e drospirenona em comprimidos 
revestidos. O método foi realizado utilizando coluna LiChroCART® 100RP (125 x 4 mm d.i., 5 µm), 
a fase móvel constituída de acetonitrila:água, 50:50 (v/v) com vazão de 1,0 mL.min-1. A detecção foi 
realizada empregando fluorescência em λex= 280 nm e λem= 310 nm para o etinilestradiol e na região de 
UV em 200 nm para a drospirenona. O etinilestradiol e a drospirenona tiveram tempo de retenção de 4,0 
e 5,7 min, respectivamente. O método foi validado de acordo com as diretrizes da USP 34. O método 
proposto apresentou vantagens sobre os relatados na literatura e pode ser considerado adequado para o 
controle de qualidade do etinilestradiol e da drospirenona em comprimidos revestidos.
Unitermos: Comprimidos revestidos/análise quantitativa. Cromatografia líquida de alta eficiência/
análise quantitativa. Etinilestradiol/determinação quantitativa. Drospirenona/determinação quantitativa. 
Detecção por fluorescência. Detecção no UV.
INTRODUCTION
Contraception is achieved mainly by inhibiting 
ovulation through the combined activity of two main 
components: estrogen and progestin. In order to ensure 
wider adherence to contraception methods, recent advances 
in oral contraceptives focused on the development of 
new formulations with fewer side effects and additional 
benefits, besides contraception (Brunton, Lazo, Parker, 
2007; Pearlstein et al., 2005; Batukan, Muderris, 2006). 
New formulations have been developed by properly 
associating low doses of ethinyl estradiol and drospirenone 
to ensure the balance between efficacy, safety and cycle 
control (Bazzote, Scheleicher, Marcon, 2005; Blode et 
al., 2000). Due to the small doses used and long term 
hormonal treatment, quality is a key feature on this 
type of formulations (Santoro et al. 2002). Several high 
performance liquid chromatography (HPLC) methods are 
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described in the literature for quantitative determination of 
associated hormones in various contraceptive formulations 
(Santoro et al., 2002; Labna et al., 2004; Denisova, 
Chistyakov, Sadchikova, 2008; Pradad, Babu, Ramana, 
2011). However, no analytical method was found in the 
literature for simultaneous quantitative determination of 
ethinyl estradiol (Figure 1A) and drospirenone (Figure 1B). 
The present study describes a simple, accurate and reliable 
validated analytical method for separation and simultaneous 
quantification of ethinyl estradiol and drospirenone in 
coated tablets using HPLC with UV and fluorescence 
detection. The method can be used in routine analysis for 
quality control of these pharmaceutical preparations.
MATERIAL AND METHODS
Instrumentation and analytical conditions
Chromatographic experiments were performed 
using a Shimadzu liquid chromatographic system 
consisting of a solvent delivery pump system model 
SCL-10Avp, an online degasification system model 
DGU-14A, an auto-injector model SIL-10AD-vp (fitted 
with a 50 µL loop), a UV detector model SPD-M10Avp 
and a fluorescence detector model RF-10Axl. The output 
signal was monitored and integrated using CLASS VP® 
software LC Workstation (Shimadzu® Corporation, Japan). 
Chromatographic separation of analytes was achieved 
using a LiChroCART® analytical column (125x4 mm 
i.d., 5 µm particle size). The fluorescence excitation and 
emission wavelengths were set at 280 and 310 nm for 
ethinyl estradiol and a UV detection was carried out at 
200 nm for drospirenone. The mobile phase was composed 
of acetonitrile and water in the ratio of 50:50 (v/v). The 
mobile phase was prepared at the beginning of the day 
and degassed by sonication for 20 min. All samples 
were filtered through a 0.45 μm Millex® HV membrane. 
All measurements were carried out with an injection 
volume of 20 μL and the mobile phase flow rate was set at 
1.0 mL.min-1. All analyses were performed at 25 ± 1 °C.
Chemicals
All reagents were of analytical grade. Acetonitrile 
and methanol (HPLC grade) were obtained from J.T. 
Baker® (Phillisburg, NJ, USA) and ultrapure water was 
obtained using a Milli-Q® water purification system 
(Millipore®, MA, USA) and used to prepare all the 
solutions.
Reference Standards
Ethinyl estradiol (99.60% purity) and drospirenone 
(99.80% purity) were kindly supplied by a local 
pharmaceutical industry.
Samples
Three samples containing ethinyl estradiol and 
drospirenone were kindly supplied by a pharmaceutical 
industry. Samples: 1 and 3 were from two available 
batches containing 0.03 mg of ethinyl estradiol and 
3.00 mg of drospirenone; sample 2: containing 0.02 mg 
of ethinyl estradiol and 3.00 mg of drospirenone and 
sample 4: simulated sample (spiked sample) containing a 
mixture of the inactive ingredients and, ethinyl estradiol 
and drospirenone standards (50, 100 and 150% of nominal 
concentration of analytes). A placebo sample was prepared 
containing: povidone 3.0%, starch 15.0%, croscarmellose 
sodium 1.0%, magnesium stearate 1.0%, macrogol 0.3%, 
hypromelose 2.0%, dye sunset yellow 0.0001% and 
lactose q.s.p. 100%.
PREPARATION OF STANDARD SOLUTION
Standard stock solutions of ethinyl estradiol 
(100.00 µg.mL-1) and drospirenone (2000.00 µg.mL-1) 
were prepared in methanol. Working standard solutions 
were prepared daily. Test solutions were prepared by 
appropriately diluting the stock solutions with a mixture 
of acetonitrile: water (50:50 v/v).
Preparation of sample solution
Twenty one coated tablets (sample 1, 2 and 3) 
were individually weighed and the mean weight was 
determined. All the 21 units were triturated and an amount 
of powder correspondent to 10 coated tablets was weighed 
and used for stock sample solution preparation. The 
powder was transferred to a 25 mL volumetric flask and 
solubilized in methanol. This mixture was sonicated for 
20 min and centrifuged at 1923.07 g for 15 min. The upper 
FIGURE 1 - Chemical structures of ethinyl estradiol (A) and 
drospirenone (B).
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and 750.0 µg.mL-1 of ethinyl estradiol and drospirenone, 
respectively) to establish the intra-day precision. The 
results were analyzed by ANOVA.
•	 Intermediate precision (inter-day)
The intermediate precision refers to the ability 
of the proposed method to reproduce measurements 
between different day’s within-laboratory variation, 
amongst different analysts or equipment from the same 
laboratory (USP, 2011). Inter-day precision was evaluated 
by injecting samples solutions prepared at lower, middle 
and higher concentrations of the analytical curve, on 
three consecutive days. All determinations were made in 
triplicate.
•	 Instrumental precision
Instrumental precision was performed to demonstrate 
the repeatability of retention time of analytes and 
corresponding areas. In this case, six determinations 
were performed, in triplicate, at the nominal working 
concentration (5.00 µg.mL-1 and 750.0 µg.mL-1 of ethinyl 
estradiol and drospirenone, respectively) on a single day. 
The repeatability of complete validation measurements 
was evaluated.
Precision was expressed as the percentage of relative 
standard deviation (%RSD) for peak area ratio (PAR) of 
ethinyl estradiol and drospirenone.
Accuracy
Accuracy is measured and expressed as percentage 
of standard analyte recovered from sample matrix by 
proposed assay procedure. Most often sample solutions 
are spiked with a known amount of standard (USP, 2011). 
The accuracy of method was evaluated in triplicate at 
three concentration levels, 50, 100 and 150% of nominal 
concentration of analyte. Standards solutions were added 
to the placebo and analyzed by the proposed method.
Robustness
The robustness of a method is its capacity to remain 
unaffected by small variations in method parameters 
(ICH 2005). In this study, the robustness of the method 
was evaluated based on following three chromatographic 
parameters: flow rate (1.0 ± 0.1 mL.min-1), temperature 
(25 ± 3 °C) and proportion of acetonitrile (50 ± 5%) in the 
mobile phase. The resolution between peaks parameter 
was examined, in triplicate, at previously fixed levels, 
above (+) and below (-) the nominal value.
Specificity
Specificity is the ability to measure accurately and 
layer was then filtered using a 0.45 µm filter (Millipore®). 
Aliquots of stock sample solution were diluted in 
acetonitrile:water (50:50 v/v) to obtain concentration 
of 2.50 µg.mL-1, 5.00 µg.mL-1 and 7.50 µg.mL-1 for 
ethinyl estradiol and 250.00 µg.mL-1, 500.00 µg.mL-1 
and 750.00 µg.mL-1 for drospirenone for samples 1 and 3. 
Sample 2 was also diluted in acetonitrile:water (50:50 v/v) 
to obtain concentration of 2.50 µg.mL-1, 5.00 µg.mL-1 and 
7.50 µg.mL-1 of ethinyl estradiol and 375.00 µg.mL-1, 
750.00 µg.mL-1 and 1125.00 µg.mL-1 of drospirenone.
Method validation
The method was validated according to the United 
States Pharmacopeia recommendations (USP, 2011) and 
AOAC INTERNATIONAL (AOAC, 2007). The following 
validation characteristics were addressed: linearity, 
detection limit, quantification limit, precision, accuracy, 
robustness and specificity.
Linearity
The linearity of an analytical procedure is its 
ability, within a definite range, to obtain results directly 
proportional to the concentration of the analyte in the 
sample (USP, 2011). Since the nominal concentration 
for the assay test is 5.00 µg.mL-1 and 750.00 µg.mL-1 for 
ethinyl estradiol and drospirenone, respectively, linearity 
was performed using six concentrations over the range 
of 0.10 to 10.00 µg.mL-1 for ethinyl estradiol and from 
15.00 to 1500.00 µg.mL-1 for drospirenone. The solutions 
were filtered using a 0.45 µm filter (Millipore®) and each 
solution was injected in triplicate into the chromatographic 
system. The analytical curve was evaluated by plotting 
concentration versus mean area. The equation was 
obtained using the least square regression procedure.
Detection limits (DL) and quantitation limits (QL)
DL and QL for the proposed analytical method 
were determined based on residual standard deviation of 
regression line (σ) and slope (s) of the analytical curve 
in accordance with the equations DL= 3.3 (σ/S) and 
QL=10 (σ/S) (USP, 2011). The detection results using UV 
and fluorescence detection were compared.
Precision
•	 Repeatability (intra-day)
Repeatability refers to the ability of the proposed 
method to reproduce measurements over a short time 
interval under same analytical conditions (USP, 2011). 
For present method, six determinations were performed in 
triplicate at nominal working concentration (5.00 µg.mL-1 
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specifically the analyte of interest in the presence of other 
components that may be expected to be present in the 
sample (USP, 2011; Ribani et al., 2004). The specificity of 
the method was tested by comparing the chromatograms 
of placebo, commercially available sample and standard 
solutions. Excipients used to prepare the placebo were 
similar to those present in the commercial formulations.
RESULTS AND DISCUSSION
Selection of the HPLC conditions
In order to obtain adequate separation and short 
time of analysis, different mobile phases were evaluated. 
Several strategies were tested to achieve a resolution 
(Rs)≥2 and short analysis time. Several proportions of 
acetonitrile:water and methanol:water in the mobile phase 
were tested. The methanol provided longer retention time 
and for that reason acetonitrile was selected for further 
method development. The best response was obtained with 
mobile phase constituted of acetonitrile:water (50:50 v/v), 
flow rate of 1.0 mL.min-1 and injection volume of 20 µL. 
The temperature was set at 25 ± 1 °C. Total run time 
was of 7 min and Rs = 5.84. Replicate (n=10) injections 
were made to ensure reproducibility and accuracy of 
measurements.
Detection
The use of fluorimetric detection allowed better 
quantification of ethinyl estradiol than the UV detection 
(Araujo, 2006). Nevertheless, drospirenone has no 
fluorescence (Figure 2). Hence, quantitative determination 
of drospirenone was made by using UV detection 
(Figure 3). 
Method validation
According to the USP (2011), method validation 
is performed to ensure that an analytical methodology 
is accurate, specific, reproducible, and rugged over 
the specified concentration range and within described 
analytical conditions.
Linearity, detection and quantification limits
Analytical curves were obtained using six points and 
triplicate injection of standards at each concentration level. 
The method showed excellent linearity over a defined 
concentration range with correlation coefficient better 
than 0.999 (Table I).
Data provides conclusive evidence of a linear 
relationship between concentration and method response. 
FIGURE 2 - Chromatograms of standard solutions. HPLC-UV 
detection at 200 nm (A), and HPLC-Fluorescence detection at 
λex=280 nm and λem=310 nm (B). Concentration: 5.00 µg.mL-1 
of ethinyl estradiol (1) and 750.00 µg.mL-1 of drospirenone (2). 
Chromatographic conditions: LiChroCART® column (125 mm x 
4 mm i.d., 5 µm particle size), mobile phase: acetonitrile:water 
(50:50 v/v), flow rate 1.0 mL.min-1, injection volume: 20 µL, 
temperature 25 ± 1 °C.
FIGURE 3 - Chromatograms of placebo solution (A), 
standard solution at 5.00 µg.mL-1 of ethinyl estradiol (1) 
and 750.00 µg.mL-1 of drospirenone (2) (B), and sample 
solution 5.00 µg.mL-1 of ethinyl estradiol (1) and 750.00 
µg.mL-1 of drospirenone (2) (C).Chromatographic conditions: 
LiChroCART® column (125 mm x 4 mm i.d., 5 µm particle 
size), mobile phase: acetonitrile:water (50:50 v/v), flow rate: 
1.0 mL.min-1, injection volume: 20 µL, temperature: 25 ± 1 °C. 
UV detection at 200 nm.
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The DL and QL for drospirenone were 4.88 µg.mL-1 and 
14.80 µg.mL-1, respectively. For ethinyl estradiol, DL and 
QL were compared using two types of detectors. Results 
obtained using fluorescence detection (DL 0.02 µg.mL-1 
and QL 0.06 µg.mL-1) were better than those obtained with 
UV detection (DL 0.14 µg.mL-1 and QL 0.41 µg.mL-1) 
(Table II).
Precision
The precision of an analytical method gives 
information on method random error. It expresses the 
closeness between a series of measurement obtained from 
multiple sampling of the same homogeneous sample under 
TABLE I - Statistical data from the analytical curve for the 
proposed HPLC method
Parameter Ethinyl estradiola Drospirenone
b
Concentration range (µg.mL-1)c 0.1 - 10 15 - 1500
Intercept 33413 56550
Slope (S) 1171850 7422.8
Correlation coefficient 0.9989 0.9990
Residual SD of the regression 
line (σ)
7197.96 10986.60
a Fluorescence detection; b UV detection; c six data points, 
triplicate injection at each concentration level
TABLE II - Results obtained for DL and QL by using two 
detectors: UV and fluorescence
HPLC-UV DL (µg.mL-1) QL (µg.mL-1)
Ethinyl estradiol 0.14 0.41
Drospirenone 4.88 14.80
HPLC-Fluorescence DL (µg.mL-1) QL (µg.mL-1)
Ethinyl estradiol 0.02 0.06
described conditions (Laban, 2004). One way ANOVA 
(single factor) was used for estimating the total variability 
of ethinyl estradiol and drospirenone intra-day precision. 
F value calculated for ethinyl estradiol and drospirenone 
by ANOVA was 1.95 and 2.59, respectively. The value 
was lower than the critical factor 3.10, showing that the 
method do not present statistical significant difference 
amongst distinct measurements (p ≤ 0.05). The results 
of % RSD, were 1.00 and 1.12% for ethinyl estradiol 
and drospirenone, respectively (intra-day precision). The 
criteria for intra-day and inter-day precision demands a 
%RSD lower than 2.0% (USP, 2011).
The % RSD inter-day precision was obtained 
by analyzing sample solution in lower, middle and 
higher concentration (nine replicates each day) on three 
consecutive days. The % RSD values ranged from 0.61 to 
1.74%. These results indicate that the developed method 
presents good precision.
Instrumental precision was calculated as %RSD. 
For migration time and peak area of 18 runs, the values 
were 0.17% and 1.06% for ethinyl estradiol and 0.31% 
and 1.97% for drospirenone, respectively. The precision 
of injection was therefore considered satisfactory.
The repeatability of the complete validation 
calculated as % RSD for migration time and peak area 
(approximately 180 runs) was 1.63% and 1.32% for 
ethinyl estradiol and 1.95% and 1.86% for drospirenone, 
respectively. The results obtained in the analysis 
of commercially available samples are shown in 
Table III.
Accuracy
The accuracy was determined by recovery test 
and results are presented in Table IV. The recovery of 
ethinyl estradiol standard was from 99.85% to 101.38%, 
and for drospirenone was from 98.70% to 102.00%. 
The recovery test and the percentage of recovery 
TABLE III - Statistical representation of the data obtained in the analysis of commercial available samples (1, 2 and 3) using the 
proposed HPLC method 
Sample Declared amount (µg/unit)
Found amount 
(µg/unit)
Relative standard 
desviation (%)
Result 
(%)
1 Ethinyl estradiola 30 29.22 0.57 97.40
Drospirenoneb 3000 2859.30 0.37 95.30
2 Ethinyl estradiola 20 21.45 0.96 107.26
Drospirenoneb 3000 2889.3 0.99 96.31
3 Ethinyl estradiola 30 32.37 0.18 107.91
Drospirenoneb 3000 2901 0.34 96.70
a Fluorescence detection; b UV detection
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were performed according to the recommendation of 
AOAC INTERNATIONAL (100 ± 2%) (AOAC, 2007). 
The obtained results confirmed the accuracy of the 
method.
Robustness
The result and the experimental range of the 
selected variables are presented in Table V, including the 
established experimental conditions (1.0 mL.min-1, 25 °C, 
acetonitrile 50%). There were no significant changes in 
the chromatographic pattern when the modifications were 
made in the experimental conditions.
The established experimental conditions presented 
a resolution of 5.84. Different resolution values were 
obtained with the modification of each factor, but none 
of them compromised the method (Rs ≥ 2) (Ribani et al., 
2004). The results presented in Table VI shows that the 
temperature has no significant effect on resolution and that 
the resolution increases with the decrease of mobile phase 
flow rate and acetonitrile concentration. Thus, within 
specified analytical conditions, the proposed method was 
considered robust.
Specificity
The specificity of the method was demonstrated 
by the absence of interference during measurements 
of ethinyl estradiol and drospirenone. The interference 
criterion for assays, especially from sample excipients, 
is defined in USP 2011. It was observed that excipients 
do not present overlapping peaks with ethinyl estradiol 
and drospirenone peaks, hence do not interfere in the 
method. Figure 3 shows that despite the presence of the 
peaks of the pharmaceutical formulation components 
(excipients), peaks of ethinyl estradiol and drospirenone 
were satisfactorily separated.
CONCLUSION
The proposed HPLC method enables the separation 
and simultaneous quantitative determination of ethinyl 
estradiol and drospirenone in coated tablets. The detection 
and quantitative determination of ethinyl estradiol in 
the presence of drospirenone is extremely difficulty 
due to enlarged concentration ratio (1:100). Although 
UV detection of ethinyl estradiol is possible, the use of 
TABLE IV - Recovery of standard ethinyl estradiol and drospirenone solution added to placebo and analyzed by the proposed 
HPLC method
Standard added to placebo 
sample (µg.mL-1)
Amount of standard  
quantified (µg.mL-1) Recovery (%)
Ethinyl estradiola 2.50 2.53 101.30
5.00 5.06 101.38
7.50 7.48 99.85
Drospirenoneb 375 382.99 102.00
750 740.50 98.73
1125 1118.54 99.45
a Fluorescence detection; b UV detection
TABLE V - Chromatographic conditions and range investigated during robustness testing
Parameter Range Investigationc Ethinyl estradiol (%)a Drospirenone (%)b
Flow rate (mL.min-1) 0.8 100.91 99.81
1.0 100.07 100.45
1.2 100.33 98.95
Temperature (°C) 22 101.53 100.34
25 100.73 99.75
28 99.76 100.95
Proportion of acetonitrile (%) 45 101.36 99.75
50 99.76 100.53
55 100.53 101.20
a Fluorescence detection; b UV detection; c triplicate injection at each range investigation
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TABLE VI - Chromatographic parameters used for robustness determination
Chromatographic parameters Low level (-)  Zero level (0) High level (+)
A – Flow rate (mL.min-1) 0.9 1.0 1.1
B – Temperature (°C) 22 25 28
C –Acetonitrile/water (v/v) 45:55 50:50 55:45
Sample n° A B C Rs
1 5,40
2 + 4,84
3 + 5,32
4 + + 4,75
5 + 4,56
6 + + 4,27
7 + + 4,58
8 + + + 4,29
fluorescence detection allowed a better quantification 
of ethinyl estradiol in low amounts. A new method was 
developed and fully validated with critical evaluation of 
specificity, injection precision, linearity, detection and 
quantitation limits, precision, accuracy and robustness, 
presented adequate performance characteristics. The 
simplicity of the method allows its use in quality control 
laboratories for routine analysis.
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